The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a ro ....The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a role in therapy.Read moreRead less
The Role Of Angiotensin-(1-7), Angiotensin Converting Enzyme-2 And The Mas Receptor In Liver Fibrosis And The Development And Maintenance Of Portal Hypertension
Funder
National Health and Medical Research Council
Funding Amount
$55,575.00
Summary
Chronic liver disease is widespread in our community, and is increasing due to fatty liver disease and viral hepatitis. Liver disease leads to permanent liver scarring, liver cancer and other life-threatening complications. This research investigates the role of a hormone system called the renin-angiotensin system in liver disease, and investigated the use of drugs that act on this system for the prevention and treatment of liver scarring and these complications.
The Role Of Adiponectin-mediated Nitric Oxide On Portal Hypertension And Liver Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$526,380.00
Summary
Liver cirrhosis is associated with high portal pressure that can result in severe bleeding and death. Adiponectin, a circulating protein, protects the liver from inflammation and scarring and may reduce portal pressure. We will characterise the mechanisms by which adiponectin induces NO and limits liver damage and determine if adiponectin treatment can reduce portal hypertension and bleeding in liver disease.
Investigation Of The Beneficial Arm Of The Renin-Angiotensin System (RAS) To Formulate Potential Therapies In Liver Diseases
Funder
National Health and Medical Research Council
Funding Amount
$71,765.00
Summary
Severe liver damage due to chronic hepatitis and other common liver diseases is now a major cause of illness and death in Australia. This project will examine how a hormone system contributes to the development of liver damage in these diseases. We will study whether drugs targeting this system can be used to reduce liver scarring and prevent the development of severe liver damage and its complication.